Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Regulation of T-cell immune responses by Nrf2 to decrease COPD exacerbations

FY 2012-13

Summary
COPD patients suffer frequent viral infections due to Human Rhinovirus and Influenza A Virus, which cause substantial morbidity and mortality. In response to cigarette smoke (CS), transcription factor Nrf2 upregulates a broad spectrum of protective defenses, including nearly all cellular antioxidants. Our laboratory has previously shown that lungs of COPD patients have a defective Nrf2 pathway and Nrf2 protects from CS-induced oxidative stress, inflammation and helps fight bacterial infection. The role of Nrf2 during viral infection is not known. Our recent findings suggest we have not only found a novel cause of virus driven COPD deaths, but also a therapeutic solution. My research from past 1 year has uncovered a novel role of Nrf2 in regulating T cell responses which are required to fight viral infections but worsen COPD symptoms. We have found that CS-exposure increased T cell inflammatory responses and caused greater lung damage in Nrf2-/- mice following virus infection and conversely, increasing Nrf2 in T cells blunted the harmful effects in vitro. We hypothesize that Nrf2 regulates the dangerous effects of T cells without compromising viral clearance and inhibits excessive pulmonary inflammation in CS-exposed mice following viral infection. To prove this we will; 1) Test the hypothesis that Nrf2 inhibits activation of T cells that destroy lung tissue in CS exposed mice following virus infection, 2) Determine whether augmenting Nrf2 by sulforaphane attenuates T cell inflammation in CS-exposed mice following virus infection and 3) Test the hypothesis that activation of Nrf2 suppresses T cell activation through upregulation of self-regulatory molecule SOCS3. Taken together, this study will identify a novel mechanism of T cell regulation and test the therapeutic potential of sulforaphane, a phytonutrient found in broccoli sprouts and potent Nrf2 activator for the treatment of viral exacerbations of COPD.
Program
CIHR Fellowship
Location
Maryland, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
270119
Name
Mccormick Sarah M
Region
Maryland
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Regulation of T-cell immune responses by Nrf2 to decrease COPD exacerbations
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cell Signaling; Copd; Flow Cytometry; Gene Expression Profiling; Immune Regulation; In Vivo Models; Investigational Therapeutics; T Cell; Translational Medicine; Viral Infection
Abstract
COPD patients suffer frequent viral infections due to Human Rhinovirus and Influenza A Virus, which cause substantial morbidity and mortality. In response to cigarette smoke (CS), transcription factor Nrf2 upregulates a broad spectrum of protective defenses, including nearly all cellular antioxidants. Our laboratory has previously shown that lungs of COPD patients have a defective Nrf2 pathway and Nrf2 protects from CS-induced oxidative stress, inflammation and helps fight bacterial infection. The role of Nrf2 during viral infection is not known. Our recent findings suggest we have not only found a novel cause of virus driven COPD deaths, but also a therapeutic solution. My research from past 1 year has uncovered a novel role of Nrf2 in regulating T cell responses which are required to fight viral infections but worsen COPD symptoms. We have found that CS-exposure increased T cell inflammatory responses and caused greater lung damage in Nrf2-/- mice following virus infection and conversely, increasing Nrf2 in T cells blunted the harmful effects in vitro. We hypothesize that Nrf2 regulates the dangerous effects of T cells without compromising viral clearance and inhibits excessive pulmonary inflammation in CS-exposed mice following viral infection. To prove this we will; 1) Test the hypothesis that Nrf2 inhibits activation of T cells that destroy lung tissue in CS exposed mice following virus infection, 2) Determine whether augmenting Nrf2 by sulforaphane attenuates T cell inflammation in CS-exposed mice following virus infection and 3) Test the hypothesis that activation of Nrf2 suppresses T cell activation through upregulation of self-regulatory molecule SOCS3. Taken together, this study will identify a novel mechanism of T cell regulation and test the therapeutic potential of sulforaphane, a phytonutrient found in broccoli sprouts and potent Nrf2 activator for the treatment of viral exacerbations of COPD.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mccormick, Sarah M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~